JP7241747B2 - 血液学的障害を治療するための化合物および組成物 - Google Patents

血液学的障害を治療するための化合物および組成物 Download PDF

Info

Publication number
JP7241747B2
JP7241747B2 JP2020523028A JP2020523028A JP7241747B2 JP 7241747 B2 JP7241747 B2 JP 7241747B2 JP 2020523028 A JP2020523028 A JP 2020523028A JP 2020523028 A JP2020523028 A JP 2020523028A JP 7241747 B2 JP7241747 B2 JP 7241747B2
Authority
JP
Japan
Prior art keywords
cancer
use according
compound
leukemia
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501145A5 (https=
JP2021501145A (ja
Inventor
ブーハー，ロバート
Original Assignee
キュリス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュリス，インコーポレイテッド filed Critical キュリス，インコーポレイテッド
Publication of JP2021501145A publication Critical patent/JP2021501145A/ja
Publication of JP2021501145A5 publication Critical patent/JP2021501145A5/ja
Priority to JP2023034551A priority Critical patent/JP7476380B2/ja
Application granted granted Critical
Publication of JP7241747B2 publication Critical patent/JP7241747B2/ja
Priority to JP2024066487A priority patent/JP2024096919A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020523028A 2017-10-31 2018-10-30 血液学的障害を治療するための化合物および組成物 Active JP7241747B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023034551A JP7476380B2 (ja) 2017-10-31 2023-03-07 血液学的障害を治療するための化合物および組成物
JP2024066487A JP2024096919A (ja) 2017-10-31 2024-04-17 血液学的障害を治療するための化合物および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579502P 2017-10-31 2017-10-31
US62/579,502 2017-10-31
PCT/US2018/058194 WO2019089580A1 (en) 2017-10-31 2018-10-30 Compounds and compositions for treating hematological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023034551A Division JP7476380B2 (ja) 2017-10-31 2023-03-07 血液学的障害を治療するための化合物および組成物

Publications (3)

Publication Number Publication Date
JP2021501145A JP2021501145A (ja) 2021-01-14
JP2021501145A5 JP2021501145A5 (https=) 2021-12-09
JP7241747B2 true JP7241747B2 (ja) 2023-03-17

Family

ID=66328095

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020523028A Active JP7241747B2 (ja) 2017-10-31 2018-10-30 血液学的障害を治療するための化合物および組成物
JP2023034551A Active JP7476380B2 (ja) 2017-10-31 2023-03-07 血液学的障害を治療するための化合物および組成物
JP2024066487A Withdrawn JP2024096919A (ja) 2017-10-31 2024-04-17 血液学的障害を治療するための化合物および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023034551A Active JP7476380B2 (ja) 2017-10-31 2023-03-07 血液学的障害を治療するための化合物および組成物
JP2024066487A Withdrawn JP2024096919A (ja) 2017-10-31 2024-04-17 血液学的障害を治療するための化合物および組成物

Country Status (26)

Country Link
US (3) US10758518B2 (https=)
EP (2) EP4410377A3 (https=)
JP (3) JP7241747B2 (https=)
KR (2) KR20240130818A (https=)
CN (2) CN117064897A (https=)
AU (3) AU2018359248B2 (https=)
BR (1) BR112020008214A2 (https=)
CA (1) CA3079628A1 (https=)
DK (1) DK3704108T3 (https=)
EA (1) EA202090497A1 (https=)
ES (1) ES2979273T3 (https=)
FI (1) FI3704108T3 (https=)
HR (1) HRP20240700T1 (https=)
HU (1) HUE067356T2 (https=)
IL (3) IL308364B2 (https=)
LT (1) LT3704108T (https=)
MX (2) MX2020003666A (https=)
MY (1) MY203827A (https=)
PH (1) PH12020550457A1 (https=)
PL (1) PL3704108T3 (https=)
PT (1) PT3704108T (https=)
RS (1) RS65572B1 (https=)
SG (1) SG11202002386WA (https=)
SI (1) SI3704108T1 (https=)
SM (1) SMT202400216T1 (https=)
WO (1) WO2019089580A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3466955T (lt) 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
EP3600270B1 (en) 2017-03-31 2023-06-14 Aurigene Oncology Limited Compounds and compositions for treating hematological disorders
HUE067356T2 (hu) * 2017-10-31 2024-10-28 Curis Inc IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
AU2020352311B2 (en) * 2019-09-24 2023-11-09 Wuhan Createrna Science And Technology Co., Ltd. IRAK inhibitor and preparation method therefor and use thereof
WO2021204589A1 (en) 2020-04-07 2021-10-14 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
IL300310A (en) * 2020-08-03 2023-04-01 Curis Inc Preparations and methods for treating diseases and disorders
MX2023005591A (es) * 2020-11-18 2023-05-29 Curis Inc Metodos de tratamiento de enfermedades y trastornos.
CN116745294A (zh) * 2020-12-25 2023-09-12 南京明德新药研发有限公司 酰胺噁唑类化合物
EP4319750A4 (en) * 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
EP4434981A4 (en) * 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
JP2025516501A (ja) * 2022-05-11 2025-05-30 キュリス，インコーポレイテッド Ｉｒａｋ４修飾化合物による疾患及び障害の治療
AU2024368208A1 (en) * 2023-10-27 2026-04-16 Curis, Inc. Methods of treating cancer associated with reduced interleukin 1 beta expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502088A (ja) 2014-01-13 2017-01-19 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
WO2017023941A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
ES2102367T3 (es) 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
EP2385041B1 (en) 2003-05-01 2013-09-18 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
EP1627869B1 (en) 2003-05-20 2012-05-02 Ajinomoto Co., Inc. Vanilloid receptor modulators
EP1628661A2 (en) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXPA06003949A (es) 2003-10-07 2006-06-27 Renovis Inc Compuestos amida como ligandos del canal de ion y su uso.
CA2563941C (en) 2004-04-22 2014-10-07 Bayer Cropscience Lp Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006053227A2 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006066174A1 (en) 2004-12-17 2006-06-22 Eli Lilly And Company Thiazolopyridinone derivates as mch receptor antagonists
DE602005009021D1 (de) 2004-12-17 2008-09-25 Lilly Co Eli Neue mch-rezeptorantagonisten
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CN101379060B (zh) 2006-02-10 2012-05-23 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
CA2644910C (en) 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds
US20080293785A1 (en) 2006-04-11 2008-11-27 Connolly Peter J Substituted benzothiazole kinase inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
EP2061786A2 (en) 2006-09-07 2009-05-27 Biogen Idec MA Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
ES2457418T3 (es) 2007-07-16 2014-04-25 Abbvie Inc. Indazoles, bencisoxazoles y bencisotiazoles como inhibidores de proteína cinasas
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
CN101790519B (zh) 2007-08-08 2013-10-16 默克雪兰诺有限公司 用于治疗多发性硬化症的结合于鞘氨醇1-磷酸(s1p)的6-氨基-嘧啶-4-羧酰胺衍生物及相关化合物
WO2009102468A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
CN102281919A (zh) 2008-11-19 2011-12-14 先灵公司 二酰基甘油酰基转移酶的抑制剂
WO2010071819A1 (en) 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
WO2010072599A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone ureas as p2x7 modulators
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
US8822447B2 (en) 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
US20130053382A1 (en) 2010-04-30 2013-02-28 Sunil Paliwal Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1)
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
EP2696873B1 (en) 2011-04-12 2022-08-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6372666B2 (ja) 2012-11-03 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング サイトメガロウイルスの阻害剤
EP2999470B1 (en) * 2013-05-22 2017-08-16 Children's Hospital Medical Center Combination therapy for mds
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EP3092226B1 (en) * 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
US9452986B2 (en) 2014-02-06 2016-09-27 Abbvie Inc. 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
AU2015275730A1 (en) * 2014-06-20 2016-12-15 Aurigene Discovery Technologies Limited Substituted indazole compounds as IRAK4 inhibitors
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
JP2018524372A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
WO2018081738A1 (en) 2016-10-28 2018-05-03 Children's Hospital Medical Center Treatment of diseases associated with activated irak
HUE067356T2 (hu) * 2017-10-31 2024-10-28 Curis Inc IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502088A (ja) 2014-01-13 2017-01-19 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
WO2017023941A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds

Also Published As

Publication number Publication date
AU2023222890B2 (en) 2025-04-17
PL3704108T3 (pl) 2024-07-22
US10758518B2 (en) 2020-09-01
MX2023010882A (es) 2023-09-27
JP2023071915A (ja) 2023-05-23
US20200345704A1 (en) 2020-11-05
NZ762393A (en) 2025-07-25
KR20200080254A (ko) 2020-07-06
PT3704108T (pt) 2024-06-11
RS65572B1 (sr) 2024-06-28
WO2019089580A1 (en) 2019-05-09
HUE067356T2 (hu) 2024-10-28
US20220370422A1 (en) 2022-11-24
FI3704108T3 (fi) 2024-05-23
ES2979273T3 (es) 2024-09-25
AU2025205341A1 (en) 2025-07-31
EP4410377A2 (en) 2024-08-07
CN111225911B (zh) 2023-09-01
IL274248B1 (en) 2024-02-01
AU2018359248B2 (en) 2023-06-01
MX2020003666A (es) 2020-08-03
DK3704108T3 (da) 2024-06-10
CA3079628A1 (en) 2019-05-09
IL308364B2 (en) 2025-02-01
HRP20240700T1 (hr) 2024-08-16
PH12020550457A1 (en) 2021-03-22
EP3704108A4 (en) 2021-08-25
SG11202002386WA (en) 2020-04-29
EP3704108B1 (en) 2024-04-24
CN111225911A (zh) 2020-06-02
US20190134010A1 (en) 2019-05-09
EA202090497A1 (ru) 2020-11-23
KR20240130818A (ko) 2024-08-29
JP2024096919A (ja) 2024-07-17
IL274248B2 (en) 2024-06-01
IL308364A (en) 2024-01-01
IL274248A (en) 2020-06-30
IL308364B1 (en) 2024-10-01
AU2023222890A1 (en) 2023-09-14
IL315025A (en) 2024-10-01
AU2018359248A1 (en) 2020-03-26
KR102697663B1 (ko) 2024-08-21
EP3704108A1 (en) 2020-09-09
JP7476380B2 (ja) 2024-04-30
JP2021501145A (ja) 2021-01-14
EP4410377A3 (en) 2024-11-13
CN117064897A (zh) 2023-11-17
LT3704108T (lt) 2024-06-25
SMT202400216T1 (it) 2024-07-09
SI3704108T1 (sl) 2024-07-31
MY203827A (en) 2024-07-19
BR112020008214A2 (pt) 2020-10-27

Similar Documents

Publication Publication Date Title
JP7241747B2 (ja) 血液学的障害を治療するための化合物および組成物
US20220339161A1 (en) Compounds and compositions for treating hematological disorders
EA051654B1 (ru) Соединения и композиции для лечения гематологических нарушений
HK40031549A (en) Compounds and compositions for treating hematological disorders
HK40104383A (zh) 用於治疗血液病的化合物和组合物
HK40031549B (zh) 用於治疗血液病的化合物和组合物

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200821

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230307

R150 Certificate of patent or registration of utility model

Ref document number: 7241747

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250